ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current employees, making a capital investment of $150,000 and adding 5 new jobs that will focus on product development.

CEO and President of ImmunoSite Technologies, LLC, Carlos Aparicio, Ph.D., who has almost 20 years experience in technical and scientific leadership in the pharmaceutical and medical devices industries, said, “ImmunoSite is perfectly positioned to support our clients’ increasing needs for worldwide automation and standardization of biological assays.  As a result, we committed to expand our headquarters to a new location in the Miramar Park of Commerce, Miramar, FL, in December 2012, where we could accommodate the increased scientific and administrative staff and the large robotic systems.”

City of Miramar Mayor Lori Moseley stated, “The city is pleased to welcome ImmunoSite Technologies to our community and is excited that their biotechnology expertise further diversifies our corporate base. It is our pleasure to have provided an expedited permitting process for the company which allowed it to become operational within a month’s time.”

“The expansion of ImmunoSite Technologies and other life science firms are the real success stories of Broward County,” said Mason Jackson, president and CEO of WorkForce One Employment Solutions.   “WorkForce One looks forward to growing this business sector by continuing to work with ImmunoSite through the recruitment and training process of their employees.”

“Floridian Community Bank partnered with ImmunoSite Technologies on their move to Miramar and expansion efforts by providing working capital financing to the company.  We are impressed with the quality of management and excited about future opportunities to continue funding the growth of ImmunoSite,” commented Scott Toth, commercial market manager for Floridian Community Bank.

Greater Fort Lauderdale Alliance president and CEO Bob Swindell added, “We are very happy that ImmunoSite Technologies is expanding in Miramar. The company’s decision to expand in Miramar is a good indicator that our efforts in growing South Florida’s strong life science cluster continue to pay off. We thank the Alliance’s Business Retention and Visitation Outreach (B.R.A.V.O) action team for working with the company through one-on-one meetings.”

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/

“Our production line kept going down and IST was instrumental in providing us with accurate data quickly so we could troubleshoot and get things back up and running.”

“We are happy with ImmunoSite’s particle testing service, and thankful to your chemists for helping to solve a solution problem and clumping.”

“The data was very useful for us for some troubleshooting aspects we had to deal with in our large aquarium system here.  It was one of those ‘prove that it isn’t this’ concepts that we ran out of instrumentation to perform.  Saved us some major headaches.”

“…good turnaround time on both emails and on testing.  IST provides exactly what we need and you are always helpful.”

“We needed help for DILUTE SOLUTION particle testing since we don’t do it often and didn’t want to invest in an instrument and operator in-house.  We are very happy to have found IST.”

”The particle testing chemists at IST were able to test our samples using a special solvent system that we don’t use and sent us a data report in just days!”

“At first, the prices seemed high, but the turnaround time and service is so great, and you were willing to work out discounts, that it is a great partnership now.”

“The best thing for us is IST’s promptness in everything!”

You may have noticed that names and organizations are witheld from the customer statements above.  This is to protect their privacy, however, if you would like to speak with IST particle testing customers, please contact IST and we will introduce you.

Leading global supplier of surface-enhancing processes and materials counts on ImmunoSite Technologies particle testing services to ensure the highest quality for coatings that protect and endure in harsh environments.

To download, please fill in the form below:

[email-download download_id="1" contact_form_id="2"]

Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement.

As part of the agreement, ImmunoSite Technologies (IST) will utilize its extensive industry expertise and experience to perform particle testing for Beckman Coulter customers using Beckman Coulter’s particle testing instrumentation. IST will employ technologies from the “Coulter Principle”, laser diffraction, dynamic light scattering, zeta potential and BET analysis to test all aspects of particulate samples.

IST employs a wide range of technologies to solve all kinds of particle analysis challenges for clients from general chemical and manufacturing to pharmaceutical and cosmetics.

IST and Beckman Coulter particle testing customers benefit from ImmunoSite Technologies’ quick sample-analysis turnaround and superior customer service—including strict confidentially of all data and samples. With 21 CFR part 11 systems available, all samples handled by IST are analyzed with superior methodologies and with the benefit of the latest particle testing technologies and systems. Additionally, all analysis procedures and results data undergo extensive reviews, ensuring that customers receive the best results possible.

ImmunoSite Technologies’ outstanding Good Laboratory Practices (GLP) status was also one of the factors in being selected as a Beckman Coulter partner. IST conducts particle testing for leading companies throughout a wide-range of industries; ranging from pharmaceuticals to various construction materials, cosmetics and more. All protocols for sample handling and data reporting exceed the current GLP standards, reinforcing IST’s commitment to addressing its customer’s requirements for quality control, regulatory compliance and auditing.

“We are extremely confident in the abilities of particle testing and the services we provide to help us solve our customers’ complex problems,” said Wade Bolton, Ph.D., CEO of IST. “This is an important adjunct to our current pharma services in immune monitoring and surveillance.”

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or follow on Facebook at http://www.facebook.com/pages/ImmunoSite-Technologies-LLC/167604859950599

About ImmunoSite Technologies

Based in Ft. Lauderdale, FL, ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) immune monitoring services to leading biotechnology, pharmaceutical, and academic organizations around the world to provide products and services that span all stages of drug discovery and development. The company is uniquely qualified to develop assays and conduct testing to assess immune status and function. IST is rapidly building a worldwide reputation for services related to qualifying, standardizing, and when appropriate, automating assays associated with cell-mediated immunity. IST services include flow cytometry, particle characterization, application development, automation, assay development and testing. By using qualified reagents, controls, standards and processes, IST-developed functional assays perform within tight specifications and yield reproducible results, helping pharmaceutical and biotechnology companies to accelerate drug discovery, document clinical relevance and reduce costs.

A privately held company, IST was formed in August, 2009, to bring together a highly qualified team of industry leading immune system research and development scientists who together have more than 100 years of experience developing and performing assays related to immune monitoring and surveillance. The IST team has been distinguished by their ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London managed CD4 Initiative. This extensive cell analysis R&D experience qualifies IST scientists to comply with complex and demanding international scientific and governmental regulations.

Press Contact: Marketing Matters
Scott Moody, Director of Public Relations
Ph: 954-925-1511
Email: scott@marketingmatters.net
Web: http://www.marketingmatters.net

Link to this release on PRWeb: http://www.prweb.com/releases/2011/04/prweb5219304.htm